ReviewFrontiers in cardiovascular medicine2025
Unravelling the role of TET2 in venous thromboembolism: insights into mechanisms and therapeutic implications.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of venous thromboembolism (VTE) may complicate not only the management of the primary disease but also significantly affect the overall quality of life and prognosis for the patient. With the increasing understanding of the incidence and risks associated with VTE, there is an imminent need for better management strategies, coupled with a wider knowledge base. In recent years, Ten-Eleven Transformation 2 (TET2) has become a subject of interest among medical scientists because of its function as DNA demethylase for the treatment of a number of hematologic and oncologic disorders. The current literature concerning the association of VTE with mutations in the TET2 gene is rather diverse in terms of outcomes and, therefore, not completely coherent. While some papers propose that TET2 has an antithrombotic effect, others point to a prothrombotic effect or a more subtle effect of TET2 on the development of thromboembolism. These different views must then be integrated in order to create the aetiologic narrative of TET2 in VTE that provides a framework for understanding the epidemiologic and clinical realities. However, there is no review on the mechanism and clinical significance of TET2 in venous thromboembolism. In this review article, the authors strived to investigate Ten-Eleven Transformation 2 (TET2) connected with venous thromboembolism (VTE), analyze its molecular mechanism features and draw clinical conclusions. It is the purpose of this work to perform a comprehensive review of the TET2 function, to elucidate its involvement in VTE development, and to discuss possible treatments based on targeting TET2. It is our understanding that the review of the current literature will offer fresh insight and research agendas for the future endeavours and practice of the significant medical speciality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.